{
    "2019-01-02": [
        [
            {
                "time": "",
                "original_text": "贝达药业点评报告:恩莎替尼申请上市,研发管线进入收获期",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "恩莎替尼",
                        "申请上市",
                        "研发管线",
                        "收获期"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "浙江药企逆势飘红：仿制药一致性评价通过量全国第一",
                "features": {
                    "keywords": [
                        "浙江药企",
                        "逆势飘红",
                        "仿制药",
                        "一致性评价",
                        "全国第一"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报:医保局调结构被数据验证,大破大立下拥抱创新升级",
                "features": {
                    "keywords": [
                        "医药生物",
                        "医保局",
                        "调结构",
                        "数据验证",
                        "创新升级"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}